Safety, Tolerability and Pharmacokinetics of a Single Intravenous Administration of SP16-a SERPIN-like, Small Peptide Agonist of the Low Density Lipoprotein-like Receptor 1-in Healthy Individuals
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2019
At a glance
- Drugs SP-16 (Primary)
- Indications Diabetes mellitus; Inflammation; Myocardial infarction; Myocardial reperfusion injury
- Focus Adverse reactions
- Sponsors Serpin Pharma
- 13 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 2 Feb 2019.
- 13 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2018 New trial record